Cuiping Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Cuiping Zhang has a total of 217 co-authors. Here are the top co-authors by number of shared publications:
- Xiaobing Fu
Tianjin Medical University, Tianjin, 300070, China; Research Center for TissueG Repair and Regeneration affiliated to the Medical Innovation Research Department, PLA General Hospital and PLA Medical College, PLA Key Laboratory of Tissue Repair and Regenerative Medicine and Beijing Key Research Laboratory of Skin Injury, Repair and Regeneration, Research Unit of Trauma Care, Tissue Repair and Regeneration, Chinese Academy of Medical Sciences, Beijing, 100048, China
35 shared publications Kui Ma
Medical Innovation Research Department, PLA General Hospital and PLA Medical College, Beijing, 100048, China
29 shared publications- Haihong Li
Department of Wound Repair and Dermatologic Surgery, Taihe Hospital, Hubei University of Medicine, Shiyan, China
22 shared publications Wenzhi Hu
Medical Innovation Research Department PLA General Hospital and PLA Medical College Beijing China
17 shared publicationsQiankun Li
Department of Tissue Repair and Regeneration, The First Medical Center, Chinese PLA General Hospital, Beijing, China
12 shared publicationsXi Liu
12 shared publications
Latest Publications
- Open Access
- 1 December 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 66, 1202-1251
Biomaterial-based extracellular vesicle delivery systems for wound healing: From fabrication to applications
- 1 December 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 66, 1202-1251
Open AccessBiomaterial-based extracellular vesicle delivery systems for wound healing: From fabrication to applications
- Open Access
- 13 April 2026
- Published by Elsevier in Materials Today Bio
- Vol. 38, 103117
Rational design of FAP-targeted sEVs delivered by microneedles for precision treatment of hypertrophic scars via ferroptosis in hypertrophic scar fibroblasts
- 13 April 2026
- Published by Elsevier in Materials Today Bio
- Vol. 38, 103117
Open AccessRational design of FAP-targeted sEVs delivered by microneedles for precision treatment of hypertrophic scars via ferroptosis in hypertrophic scar fibroblasts
- Open Access
- 22 February 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Bioengineered probiotics derived bacterial extracellular vesicle as bioactive nanocarrier for the local VEGF expression to accelerate wound healing
The angiogenesis is a pivotal process during wound healing. Its deficiency usually causes diminished oxygen and nutrient conveyance, compromising the cell
- 22 February 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Open AccessBioengineered probiotics derived bacterial extracellular vesicle as bioactive nanocarrier for the local VEGF expression to accelerate wound healing
The angiogenesis is a pivotal process during wound healing. Its deficiency usually causes diminished oxygen and nutrient conveyance, compromising the cell
- Open Access
- 22 January 2026
- Published by Oxford University Press (OUP) in Regenerative Biomaterials
- Vol. 13
Integrated platform for EV separation and controlled release based on gelatin microspheres for diabetic wound treatment
Diabetic wounds exhibit impaired healing owing to multiple pathological factors and current treatment options remain limited, underscoring the urgent need for novel therapeutic strategies. Extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs) are emerging as promising candidates for wound healing. However, the process from isolation to application of EVs is complex and time-consuming, which probably influences the activity and the therapeutic effects of EVs. To address these issues, we created the integrated platform for EV separation and controlled release. Gelatin microspheres (GMS) were prepared and functionalized with the variable domain of heavy-chain-only antibodies (GMS-VHH). GMS-VHH enabled the efficient capture of CD9-positive EVs in the culture supernatant of MSCs, forming EVs-loaded gelatin microspheres (GMS@EVs). The characterization of EVs demonstrated that the GMS-VHH isolation method outperformed traditional ultracentrifugation in terms of EV structural integrity. GMS@EVs exhibited excellent biocompatibility and promoted the proliferation of epidermal keratinocytes in vitro. In addition, the controlled release and the therapeutic efficacy of GMS@EVs were also observed in the treatment of diabetic wounds. Transcriptomic analysis illustrated that the wound healing-related genes were significantly upregulated and the pro-inflammatory genes as well as the wound healing-impaired genes were downregulated. Collectively, this study introduces a “ready-to-use” platform for EV isolation and controlled release, providing a promising strategy for diabetic wound repair.
- 22 January 2026
- Published by Oxford University Press (OUP) in Regenerative Biomaterials
- Vol. 13
Open AccessIntegrated platform for EV separation and controlled release based on gelatin microspheres for diabetic wound treatment
Diabetic wounds exhibit impaired healing owing to multiple pathological factors and current treatment options remain limited, underscoring the urgent need for novel therapeutic strategies. Extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs) are emerging as promising candidates for wound healing. However, the process from isolation to application of EVs is complex and time-consuming, which probably influences the activity and the therapeutic effects of EVs. To address these issues, we created the integrated platform for EV separation and controlled release. Gelatin microspheres (GMS) were prepared and functionalized with the variable domain of heavy-chain-only antibodies (GMS-VHH). GMS-VHH enabled the efficient capture of CD9-positive EVs in the culture supernatant of MSCs, forming EVs-loaded gelatin microspheres (GMS@EVs). The characterization of EVs demonstrated that the GMS-VHH isolation method outperformed traditional ultracentrifugation in terms of EV structural integrity. GMS@EVs exhibited excellent biocompatibility and promoted the proliferation of epidermal keratinocytes in vitro. In addition, the controlled release and the therapeutic efficacy of GMS@EVs were also observed in the treatment of diabetic wounds. Transcriptomic analysis illustrated that the wound healing-related genes were significantly upregulated and the pro-inflammatory genes as well as the wound healing-impaired genes were downregulated. Collectively, this study introduces a “ready-to-use” platform for EV isolation and controlled release, providing a promising strategy for diabetic wound repair.
- Open Access
- 12 January 2026
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (3) , 1368-1387
Bacterial extracellular vesicles as bioactive nanocarriers for wound treatment
- 12 January 2026
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (3) , 1368-1387
Open AccessBacterial extracellular vesicles as bioactive nanocarriers for wound treatment
- Open Access
- 9 January 2026
- Published by OAE Publishing Inc. in Extracellular Vesicles and Circulating Nucleic Acids
- Vol. 7 (1) , 16-9
Selenized neural stem cell exosomes for CNS trauma repair
A recent study on Cell Reports Medicine by Wang et al. introduces a hybrid exosome platform - selenized neural stem cell-derived exosomes (SeNExo) - that couples the biological functionality of neural stem cell exosomes with the antioxidant power of ultrasmall nanoselenium. SeNExo crosses the blood-brain barrier via apolipoprotein E (APOE)-lipoprotein receptor-associated protein-1 (LRP1) interaction, scavenges reactive oxygen species, and restores glial-neuron homeostasis. It demonstrates potent therapeutic efficacy in both traumatic brain injury and spinal cord injury mouse models. This work highlights a promising direction for engineering multifunctional, cell-free nanotherapeutics for central nervous system repair.
- 9 January 2026
- Published by OAE Publishing Inc. in Extracellular Vesicles and Circulating Nucleic Acids
- Vol. 7 (1) , 16-9
Open AccessSelenized neural stem cell exosomes for CNS trauma repair
A recent study on Cell Reports Medicine by Wang et al. introduces a hybrid exosome platform - selenized neural stem cell-derived exosomes (SeNExo) - that couples the biological functionality of neural stem cell exosomes with the antioxidant power of ultrasmall nanoselenium. SeNExo crosses the blood-brain barrier via apolipoprotein E (APOE)-lipoprotein receptor-associated protein-1 (LRP1) interaction, scavenges reactive oxygen species, and restores glial-neuron homeostasis. It demonstrates potent therapeutic efficacy in both traumatic brain injury and spinal cord injury mouse models. This work highlights a promising direction for engineering multifunctional, cell-free nanotherapeutics for central nervous system repair.
- Top Cited PapersOpen Access
- 1 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Research
- Vol. 9
Hypoxia-Challenged sEVs-Engineered Nanofiber Scaffolds Accelerate Diabetic Wound Healing via Reversing Cellular Dysfunction of Skin Repair Cells
The persistent hyperglycemic microenvironment in diabetic wounds causes dysfunction of repair cells, resulting in impaired angiogenesis and disorganized extracellular matrix (ECM) deposition. Small extracellular vesicles (sEVs) derived from hypoxia-challenged chorionic plate mesenchymal stem cells (CP-MSC-sEVs Hypo ) have been explored as novel acellular therapeutics. However, the effects of oxygen tension during culturing parent cells on the pro-regenerative efficacy and mechanisms of CP-MSC-sEVs have not been systematically investigated. In addition, their rapid clearance and limited interaction with target cells at wound sites constrained therapeutic efficacy. In this study, oxygen tension was first optimized systematically during the precondition of CP-MSCs to improve the pro-regenerative properties of the derived sEVs Hypo . Then, sEVs Hypo -engineered nanofiber scaffolds were fabricated to achieve the sustained release of sEVs Hypo at wound sites by polydopamine (PDA)-mediated interfacial adhesion. In vitro experiments revealed that sEVs obtained under 5% oxygen tension (sEVs Hypo-5% ) exhibited the most pronounced angiogenic and collagen-regenerative performance. Furthermore, small RNA sequencing and bioinformatic analyses revealed that miR-21-5p was the most abundant miRNA in sEVs Hypo-5% , and functional rescue assays validated that miR-21-5p was the key mediator of endothelial activation and ECM remodeling. To improve the bioavailability of sEVs Hypo-5% , PDA was leveraged to immobilize sEVs Hypo-5% onto a biocompatible, ECM-mimicking poly(ε-caprolactone) nanofiber scaffold to achieve high loading efficacy and sustained release. In a full-thickness diabetic wound model, the sEVs Hypo-5% -loaded nanoscaffold accelerated wound closure and achieved superior pro-healing effects on D14 via enhancing neovascularization and ECM deposition, as confirmed by histological and immunofluorescence analyses. Collectively, this sEVs Hypo-5% -loaded nanoscaffold achieved efficient immobilization and sustained delivery of sEVs Hypo-5% to promote angiogenesis and matrix repair by endogenously delivering miR-21-5p at diabetic wound sites, with strong potential for clinical translation.
- 1 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Research
- Vol. 9
Top Cited PapersOpen AccessHypoxia-Challenged sEVs-Engineered Nanofiber Scaffolds Accelerate Diabetic Wound Healing via Reversing Cellular Dysfunction of Skin Repair Cells
The persistent hyperglycemic microenvironment in diabetic wounds causes dysfunction of repair cells, resulting in impaired angiogenesis and disorganized extracellular matrix (ECM) deposition. Small extracellular vesicles (sEVs) derived from hypoxia-challenged chorionic plate mesenchymal stem cells (CP-MSC-sEVs Hypo ) have been explored as novel acellular therapeutics. However, the effects of oxygen tension during culturing parent cells on the pro-regenerative efficacy and mechanisms of CP-MSC-sEVs have not been systematically investigated. In addition, their rapid clearance and limited interaction with target cells at wound sites constrained therapeutic efficacy. In this study, oxygen tension was first optimized systematically during the precondition of CP-MSCs to improve the pro-regenerative properties of the derived sEVs Hypo . Then, sEVs Hypo -engineered nanofiber scaffolds were fabricated to achieve the sustained release of sEVs Hypo at wound sites by polydopamine (PDA)-mediated interfacial adhesion. In vitro experiments revealed that sEVs obtained under 5% oxygen tension (sEVs Hypo-5% ) exhibited the most pronounced angiogenic and collagen-regenerative performance. Furthermore, small RNA sequencing and bioinformatic analyses revealed that miR-21-5p was the most abundant miRNA in sEVs Hypo-5% , and functional rescue assays validated that miR-21-5p was the key mediator of endothelial activation and ECM remodeling. To improve the bioavailability of sEVs Hypo-5% , PDA was leveraged to immobilize sEVs Hypo-5% onto a biocompatible, ECM-mimicking poly(ε-caprolactone) nanofiber scaffold to achieve high loading efficacy and sustained release. In a full-thickness diabetic wound model, the sEVs Hypo-5% -loaded nanoscaffold accelerated wound closure and achieved superior pro-healing effects on D14 via enhancing neovascularization and ECM deposition, as confirmed by histological and immunofluorescence analyses. Collectively, this sEVs Hypo-5% -loaded nanoscaffold achieved efficient immobilization and sustained delivery of sEVs Hypo-5% to promote angiogenesis and matrix repair by endogenously delivering miR-21-5p at diabetic wound sites, with strong potential for clinical translation.
- Top Cited PapersOpen Access
- 1 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Research
- Vol. 9
Engineering Bacterial Extracellular Vesicles as Nanoweapons to Fight against Bacterial Infections
The overuse and misuse of antibiotics have led to widespread resistance in bacteria, which makes infections difficult to treat. The insufficient prevention measures, limited treatment options, and delayed antibiotic developments call for immediate global actions to discover effective and safe treatments for bacterial infections. Over the past decades, more and more studies have found that bacterial extracellular vesicles (BEVs) secreted by bacteria with nanoscale size, lipid bilayer structure, pathogen-associated molecular patterns, and inherent bioactive substances are the ideal candidates for bacterial infection treatment. Meanwhile, advanced engineering approaches have further endowed these BEVs with more customizable properties to effectively fight against bacterial infections. Herein, the present review begins with an overview of the biogenesis and biocomponents of BEVs to better comprehend their bioactivities against bacterial infections. Their isolation and engineering approaches are then introduced, with an emphasis on the diverse genetic, physical, and chemical strategies to functionalize them with desirable capacities for the optimal treatment of bacterial infections. Recent advances in exploring the natural BEVs as antibacterial and antiadhesion agents, as well as the engineered BEVs as vaccine antigens, vaccine adjuvants, and delivery nanocarriers, are expounded successively. Discussions on the new trend of engineering BEVs as nanoweapons to combat bacterial infections, in terms of advantages and challenges, are provided at the end to expedite these BEV-based therapeutic modalities for bacterial infections from bench to bedside.
- 1 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Research
- Vol. 9
Top Cited PapersOpen AccessEngineering Bacterial Extracellular Vesicles as Nanoweapons to Fight against Bacterial Infections
The overuse and misuse of antibiotics have led to widespread resistance in bacteria, which makes infections difficult to treat. The insufficient prevention measures, limited treatment options, and delayed antibiotic developments call for immediate global actions to discover effective and safe treatments for bacterial infections. Over the past decades, more and more studies have found that bacterial extracellular vesicles (BEVs) secreted by bacteria with nanoscale size, lipid bilayer structure, pathogen-associated molecular patterns, and inherent bioactive substances are the ideal candidates for bacterial infection treatment. Meanwhile, advanced engineering approaches have further endowed these BEVs with more customizable properties to effectively fight against bacterial infections. Herein, the present review begins with an overview of the biogenesis and biocomponents of BEVs to better comprehend their bioactivities against bacterial infections. Their isolation and engineering approaches are then introduced, with an emphasis on the diverse genetic, physical, and chemical strategies to functionalize them with desirable capacities for the optimal treatment of bacterial infections. Recent advances in exploring the natural BEVs as antibacterial and antiadhesion agents, as well as the engineered BEVs as vaccine antigens, vaccine adjuvants, and delivery nanocarriers, are expounded successively. Discussions on the new trend of engineering BEVs as nanoweapons to combat bacterial infections, in terms of advantages and challenges, are provided at the end to expedite these BEV-based therapeutic modalities for bacterial infections from bench to bedside.
- Open Access
- 31 October 2025
- Published by Wiley in Exploration
- Vol. 5 (6)
Activating Ferroptosis of M1 Macrophages: A Novel Mechanism of Asiaticoside Encapsuled in GelMA for Anti‐Inflammation in Diabetic Wounds
Diabetic wounds are characterized by chronic inflammation, partly due to the persistent accumulation of pro‐inflammatory M1 macrophages. Asiaticoside (AS), a triterpenoid extracted from Centella asiatica , has known anti‐inflammatory effects in several diseases, but the underlying mechanisms in diabetic wounds are still unclear. This study reveals that AS alleviates inflammation in diabetic wounds by activating ferroptosis of M1 macrophages. In vitro, AS reduces the number of M1 macrophages in a high glucose microenvironment and their secretion of proinflammatory cytokines with concurrent induction of ferroptosis. Further investigation shows that AS‐activated ferroptosis is attributed to the downregulation of ferroportin 1 (FPN1) and ferritinophagy‐induced degradation of ferritin heavy chain 1 (FTH1), which together increase the amount of intracellular free ferrous ions (Fe 2+ ). In vivo, AS‐encapsulated gelatin‐methacryloyl hydrogels accelerates diabetic wound healing and shortens the inflammatory period by activating ferroptosis of M1 macrophages with the reduced expression of FPN1 and FTH1. These results suggest a promising AS‐based strategy for treating inflammatory diseases associated with excessive activation of M1 macrophages.
- 31 October 2025
- Published by Wiley in Exploration
- Vol. 5 (6)
Open AccessActivating Ferroptosis of M1 Macrophages: A Novel Mechanism of Asiaticoside Encapsuled in GelMA for Anti‐Inflammation in Diabetic Wounds
Diabetic wounds are characterized by chronic inflammation, partly due to the persistent accumulation of pro‐inflammatory M1 macrophages. Asiaticoside (AS), a triterpenoid extracted from Centella asiatica , has known anti‐inflammatory effects in several diseases, but the underlying mechanisms in diabetic wounds are still unclear. This study reveals that AS alleviates inflammation in diabetic wounds by activating ferroptosis of M1 macrophages. In vitro, AS reduces the number of M1 macrophages in a high glucose microenvironment and their secretion of proinflammatory cytokines with concurrent induction of ferroptosis. Further investigation shows that AS‐activated ferroptosis is attributed to the downregulation of ferroportin 1 (FPN1) and ferritinophagy‐induced degradation of ferritin heavy chain 1 (FTH1), which together increase the amount of intracellular free ferrous ions (Fe 2+ ). In vivo, AS‐encapsulated gelatin‐methacryloyl hydrogels accelerates diabetic wound healing and shortens the inflammatory period by activating ferroptosis of M1 macrophages with the reduced expression of FPN1 and FTH1. These results suggest a promising AS‐based strategy for treating inflammatory diseases associated with excessive activation of M1 macrophages.